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ABSTRACT
Hidradenitis suppurativa (HS) is a chronic inflammatory disease associated with insulin resistance (IR). 
Retinol binding protein 4 (RBP4) and ghrelin are two bioactive proteins that have been involved in glucose 
metabolism and IR, but also in the regulation of immune and inflammatory processes.The aim of this study 
was to determine the serum levels of RBP4 and ghrelin in patients with HS, and toassessthe 
possiblerelationship between these levels andIR, disease severity and HS risk. A total of 137 subjects (77 
HS-patients and 60 controls) without diabetes mellitus were enrolled in thiscross-sectional study.Patients 
with HS had significantly higher RBP4 but lower ghrelin plasma levels than controls, independently of body 
mass index (BMI). Serum RBP4 levels were positively correlatedto disease severity and IR in HS patients. 
However, we found no association between ghrelin levels and any clinical or laboratory parameters. 
Moreover, high serum RBP4and low ghrelin levels were associated with an increased risk for HS. Our results 
suggest that high RBP4 levels may be a surrogate biomarker for IR in patients with HS. Moreover,increased 
RBP4 and decreased ghrelin levels could also be independent risk factors for the development of HS.
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1 BACKGROUND
Hidradenitis suppurativa (HS) is a chronic, inflammatory, skin disease of the hair follicle. The pathogenesis of 
HS remains largely uncertain, although current evidence suggeststhe existence of an early phase of immune 
activation with progression to chronic inflammation.[1]In this sense, several pro-inflammatory cytokines, such 
as tumor necrosis factor-alpha (TNF-α), interleukin (IL)-1, IL-10 and IL-17 are considered to play a pivotal 
role in the HS pathogenic process.[1,2] Besides,someadipokines which can modulatepro-inflammatory 
cytokines levels, havealso been recently related to HS pathogenesis.[3,4]
HS patients exhibitan increased prevalence of subclinical atherosclerosis andhigh risk for 
majorcardiovascular (CV) events and CV mortality.[5-8] Furthermore, an elevated prevalence of metabolic 
disorders, including metabolic syndrome (MS),[9]insulin resistance (IR)[10]and type 2 diabetes mellitus 
(T2DM)[11]has also been reported in these patients. IR, a crucial pathophysiological factor for the 
development of MS and T2DM, and accelerated atherogenesis has been related to the chronic systemic 
inflammation state found inHS.[6,10] In this regard, it has been suggested thatraisedblood levels of certain pro-
inflammatory cytokines involved in HS pathogenesis, such as IL-1 and IL-6,may also induce a pro-
atherogenic and IR-adipokine pattern in HS patients.[1]
Plasma retinol-binding protein 4 (RBP4) is a 21-kDa protein that belongs to the lipocalin family and is the 
specific carrier for retinol in the blood circulation. It delivers vitamin A from the liver stores to the peripheral 
tissues.[12]Moreover, RBP4 alsoacts as a pro-inflammatory adipokine and has been recognized as a 
biomarker of IR in patients with obesity and T2DM, since it can impair insulin signaling.[12-14]Besides, this 
adipocyte-secreted hormone has also been involved in the atherosclerotic process and CV disease.[12]Thus, 
it has been suggested that inflammation may be the crucial pathway through which RBP4 might exert its role 
in the pathogenesis of IR and CV disease.[12,15]
Ghrelin, a peptide predominantly secreted by the stomach, is another emerging IR-related biomarker which 
also plays a role in modulating immune responses and inflammatory processes.[16] The secretion of both 
molecules,RBP4 and ghrelin,are dysregulated in several chronic inflammatory conditions.[17,18]
2 QUESTIONS ADDRESSED
We investigated whether there are differences in serum RBP4 and ghrelin levels in HS-patients compared to 
healthy controls. Furthermore, we sought to assess whether there is any relationship between these levels 
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 3 STUDY DESIGN
3.1 Participants and protocol
Cross-sectional study including 137 participants (77 HS patients and 60 controls) recruited from our 
Dermatology outpatient clinic at the University Hospital Marques de Valdecilla (Santander, Northern Spain). 
Patients were ≥18 years and fulfilled the diagnostic criteria for HS.[19] The control group was set up with 
hospital medical staff and subjects who had been admitted at the Dermatology Department because of non-
inflammatory disorders.The research protocol was approved by the local ethics committee, and all the 
participants gave written informed consent.
Exclusion criteria, clinical evaluation, and laboratory studies have been previously described.[3,10] Briefly, 
patients or controls with a history of CV events, DM and other endocrine diseases, chronic renal or liver 
failure, and/or other inflammatory cutaneous or systemic diseases, or taking drugs (in the previous 6 months) 
affecting carbohydrate metabolism, were excluded from the study. The severity of HS was assessed by the 
HS Physician Global Assessment (HS-PGA); HS was classified as moderate-severe-very severe (PGA ≥3) 
and as minimal-mild HS (PGA<3).
All the participants provided information on demographic features and past medical history. Body height and 
weight, body mass index (BMI), waist circumference (WC), systolic blood pressure (BP) and diastolic BP 
were measured in all patients and controls. Body mass index (BMI) was calculated as weight (kg)/ [height 
(m)]2.
Blood samples were collected after overnight fasting. Glucose and insulin levels, glycated hemoglobin 
(HbA1c), triglycerides, serum total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), low-density 
lipoprotein cholesterol (LDL-c) and high-sensitivity C-reactive protein (hs-CRP) were assessed in all 
participants.MS was diagnosed by the presence of three or more criteria according to the National 
Cholesterol Education Program´s Adult Treatment Panel III (ATP III).[20]The degree of IR was calculated 
using the homeostatic model assessment for IR (HOMA-IR) expressed as fasting insulin level (µIU/ml) x 
fasting glucose level (mg/dl)/405. IR was diagnosedifHOMA-IR >2.5.[10] Serum levels of RBP4 and ghrelin 
were analyzed byenzyme-linked immunosorbent assay (Sigma-Aldrich Co. LLC, St. Louis, MO, USA). RBP4 
andghrelin levels were expressed as g/ml and as ng/l, respectively. Intra-and inter-assay coefficients of 
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3.2 Statistical analysis
Results were expressed as numbers (percentage), meanstandard deviation (SD) or median and 
interquartile range (IQR), as appropriate.Mann-Whitney U-test and Chi-squared or Fisher testswere used to 
compare quantitative and qualitative variables respectively. To evaluate the relationship between serum 
RBP-4 and ghrelin levels and HOMA-IR, Pearson’s correlation was used. Moreover, forward stepwise 
multivariable logistic regression models were built to assess the potential association between both proteins 
and IR, HS risk and HS severity. 
4 RESULTS
4.1 Baseline features and serum RBP4 and ghrelin levels
Demographic, clinical and laboratory data of HS-patients and controls are summarized in Table I. There were 
no significant differences regarding age, sex, HbA1c, LDL-c and triglyceride levels. Compared with the 
control group, patients with HS displayed significantly higher values of BMI, WC, BP, hs-CRP, fasting 
glucose, fasting insulin, HOMA-IR index and prevalence of IR and MS.Moreover, HS-patients had lower 
serum HDL-c levels than the control group. RBP4 was significantly higher in HS-patients(59.3 g/ml47.2-
72.7 vs. 38.5g/ml34.7-44.3; p<0.0001) whilst serum ghrelin levels were significantly decreased in HS-
patients compared to controls (50.0 ng/ml 50.0-186.3 vs. 210.5 ng/ml 117.7-302.9; p<0.0001). These 
differences in RBP4 and ghrelin concentrations remained significant after adjusting by age, sex and BMI.
4.2 Association of RBP4 and ghrelin with IR and severity of HS
In patients with HS, we found a significantly positive correlation between RBP4 levels and IR (r=0.390; 
p=0.001) and disease severity (HS-PGA≥3) (r=0.639; p<0.0001), once adjusting for age, sex and BMI. 
However, no correlation was found between plasma ghrelin concentrations and clinical or laboratory 
parameters.
Circulating RBP4 levels were significantly higher in patients with HS-PGA score≥3 than in those with 
minimal-mild HS (HS-PGA score<3)(67.7 60.5-77.5 vs. 47.0 45.6-55.1;p<0.0001). However, no 
significant differences were observed in ghrelin concentrations between both HS-PGA groups (56.1 50.0-
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4.3 Influence of RBP4 and ghrelin on the risk for HS
Table 2 shows the results of the logistic regression analysis of independent variables considered to influence 
HS risk, adjusted by age, sex,BMI, IR, and active tobacco use. Thus, raised serum levels of RBP4 (above 
the median), and lower levelsof ghrelin (below the median) were related to an increased risk for HS 
development (OR 14.50CI 95%, 4.55-46.19]; p<0.0001, and OR 3.86 CI 95%, 1.32-11.27]; p=0.013, 
respectively). The inclusion of additional covariables, such as serum hs-CRP levels, BP or MS to the 
regression model did not virtually change theseresults. 
5 CONCLUSIONS
This is the first study, to our knowledge, that assesses RBP4 and ghrelin concentrations in patients with HS. 
We found that serum RBP4 levels were significantly increased in HS-patients and positively correlated with 
disease severity. In this regard, increased plasma levels of this adipokine have also been found in other 
cutaneous diseases, such as contact dermatitis [21]and psoriasis. [22]Moreover, raised RBP4 concentrations in 
our study were associated with an increased risk for HS, suggesting that this adipokine might play a role in 
the pathogenesis of HS.In this respect, it should be noted that RBP4 acts as an immunomodulatory 
adipocytokine and may induce the release of pro-inflammatory mediators, including TNF-α, IL-1 and IL-
6.[12]Furthermore, in our HS-patients, serum RBP4 levels were positively associated with IR even after 
adjustment for BMI, suggesting that other factors independent of obesity might be implicated in such an 
association. It is known that RBP4 may inhibit insulin signaling in adipocytes by inducing the release of 
classic pro-inflammatory mediators from macrophages.[15]These factssuggest that RBP4 might represent a 
mechanistic link between the pathological inflammatory process of HS and the development of IR in patients 
with this disease.
On the other hand, ghrelin is a pleiotropic peptide-hormone/cytokine that exerts an anti-inflammatory 
function,[16,23] although its production may also be directly inhibited by pro-inflammatory mediators.[24]In our 
study, serum ghrelin levels were significantly lower in HS-patients than in controls, irrespective of BMI. In this 
regard, the pro-inflammatory cytokines implicated in the chronic inflammatory process of HS might have 
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studies have found an inverse correlation.[25]However, we did not find any relationship between serum ghrelin 
levels and IR in HS-patients. In this sense, it is tempting to speculate that ghrelin secretion in HS patients 
might be influenced by an increase of pro-inflammatory cytokines, leading to a decrease in its serum 
levels.Besides, we have also found that serum ghrelin levels were negatively related to the risk for 
developing HS, although we cannot explain this protective finding through a beneficial effect on IR.
In conclusion, we found that serum RBP4 levels were significantly increased and serum ghrelin 
concentrations significantly decreased in HS-patients.Furthermore,our results suggest that high RBP4 levels 
may be a surrogate biomarker for IR in patients with HS. Finally,increased serum RBP4 and decreased 
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Age, yrs 42.7  11.7 45.7  13.0 0.16
Sex, male (%) 48.1 51.7 0.67
Active smoking, % 66.2 18.3 <0.0001
BMI, Kg/m2 29.5  5.4 26.6  4.5 0.001
Waist perimeter, cm 99.9  13.7 91.7  13.7 0.001
SBP, mm Hg 133.1  15.7 124.8  15.6 0.002
DBP, mm Hg 82.4  13.6 77.3  8.1 0.012
hs-CRP, mg/dl 0.42 (0.18-0.89) 0.10 (0.10-0.20) <0.0001
HbA1c, % 5.2  0.6 5.2  0.3 0.63
LDL-c, mg/dl 116.3  32.5 122.9  29.2 0.22
HDL-c, mg/dl 46.0 (41.5-56.5) 52.5 (46.3-70.5) 0.001
Triglycerides, mg/dl 100.3  47.7 98.1  66.7 0.82
Fasting plasma glucose, mg/dl 94.6  13.8 89.1  8.1 0.004
Fasting plasma insulin, µIU/ml 10.8 (5.7-17.2) 7.5 (5.0-10.8) 0.007
HOMA-IR 2.3 (1.1-3.8) 1.5 (0.9-2.3) 0.006
Insulin Resistance, % 46.8 20.0 0.001
Hypertension, % 18.2 15.0 0.62
Dyslipidemia, % 13.2 16.7 0.57
Metabolic Syndrome, % 32.5 11.7 0.004
Ghrelin, ng/ml 50.0 (50.0-186.3) 210.5 (117.7-302.9) <0.0001
RBP4, g/ml 59.3 (47.2-72.7) 38.5 (34.7-44.3) <0.0001
Table 1. Demographic, clinical and laboratory findings of patients with HS and controls
BMI, body mass index; HbA1c, glycated hemoglobin; SBP, systolic blood pressure; DBP, diastolic blood pressure; hs-CRP: high-sensitive 
C-reactive protein; LDL-c, low-density lipoprotein; HDL-c, high-density lipoprotein; HOMA-IR, Homeostatic model assessment for insulin 
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-coefficient OR (CI 95%) p
Age, yrs. -0.060 0.94 (0.90-0.98) 0.007
Active smoking, yes 2.882 17.85 (5.32-59.82) <0.0001
Insulin Resistance, yes 1.656 5.24 (1.55-17.72) 0.008
Ghrelin (median), ng/ml* 1.351 3.86 (1.32-11.27) 0.013
RBP4 (median),g /ml** 2.683 14.50 (4.55-46.19) <0.0001
Table 2. Adjusted risk factors for HS development.
* Ghrelin levels below median (<130 ng/ml). ** RBP4 levels above the median (>47.3 ng/ml) 
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